Active Ingredient(s): Ertugliflozin + Sitagliptin Phosphate
FDA Approved: * December 19, 2017
Pharm Company: * MERCK SHARP DOHME
Category: Diabetes

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Steglujan Overview

Sitagliptin, sold under the brand name Januvia among others, is an anti-diabetic medication used to treat type 2 diabetes.[4] In the United Kingdom it is listed as less preferred than metformin or a sulfonylurea.[5] It is taken by mouth.[4] It is also available in the fixed-dose combination medication sitagliptin/metformin (Janumet, Janumet XR).[4] Common side effects include headaches, swelling of the legs, and upper respiratory...

Read more Steglujan Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Steglujan Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Ertugliflozin + Sitagliptin Phosphate
  • Tablet: 15mg + 100mg, 5mg + 100mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Steglujan: (2 results)

Sorted by National Drug Code
  • 0006-5367 Steglujan Oral Tablet, Film Coated by Merck Sharp & Dohme Corp.
  • 0006-5368 Steglujan Oral Tablet, Film Coated by Merck Sharp & Dohme Corp.

Drugs with one or more similar ingredients: (9 results)